Tue 22 November 2011
Hosted by: Fasken Martineau
Organised by: Asia-Pacific Technology Network
Chair
Speakers
In a relatively short space of time, Western thinking about Chinese pharma R&D capabilities has gone from scepticism to an acceptance that China is a suitable site for Big Pharma research labs, while CRO outsourcing activities have accelerated too. Pharma companies are now displaying unprecedented levels of commitment to China-based R&D - complete with large-scale, eight-figure financial investments. Their commitment is often coupled with the shutting down of sites in Europe and the US. In addition to the need for increased cost-effectiveness, the move for many forward-thinking pharma companies is motivated by their desire to tap - or at least try to - China’s massive (and increasing) healthcare market and the profit-potential housed there.
Location: Fasken Martineau, 17 Hanover Square London W1S 1HU
Nearest tube station: Oxford Circus
Timing: Registration from 17:00: seminar from 17:30 - 19.15 (followed by refreshments)
Pricing:
To Register your interest- please send your details (name, institutional affiliation, email address, phone number - and the category you come under) to biz22@aptn.org
Nick Stephens
Nick has been a Director of RSA since 1986 and joined the business full-time in 1995. In 2000 he became Managing Director of RSA Consulting Ltd - the RSA "group" company. Following a major restructure in September 2005 Nick took up a new position as CEO. In this role he has led the transformation of RSA into a truly global company launching new wholly-owned businesses in Singapore, London, New Jersey, France, Germany and Switzerland and a JV in China. Nick studied Law at the University of East Anglia and Business at Cranfield and has broad commercial experience gained through various roles in metals trading, healthcare, pharmaceuticals and the British National Health Service as well as from his time at RSA.
Dr Patrick Keohane. MB, BS, MRCP.
Joined Astrazeneca in Sweden in 2002, initially to lead the Clinical Science global function, then served as Clinical VP for the GI Area. Head of Japan R&D, then AsiaPacific and Japan R&D from 2006, responsible for 800 R&D and Marketing Company staff in 14 Markets and including China, Japan, India, and Australia. In 2011 built and staffed a new global Payer Evidence function to serve Commercial and R&D across the small and large molecule portfolios and inline Brands. In 1984 joined Eli Lilly to co-lead the Nizatidine development from phase 1 to Launch in Europe. Subsequently served in various Commercial and R&D management positions, with involvement in regulatory, media, legal and external influencing activities. These include four years as UK and Ireland Medical Director, moving to Indianapolis as Clinical Director for Diabetes and Endocrinology (late discovery through Phase 3 global development, large and small molecules and devices) responsible for Humalog ( first analog insulin) and Evista, to Frankfurt as Regional Diabetes Care Director, and European Regional Medical Director responsible for 400 staff in 11 affiliates. Initially trained as a Gastroenterologist working in the NHS and as a Research Fellow for the Medical Research Council. Regular invited speaker or chair at external meetings, including BioPartnering, BioAsia, SFDA/EU Commission, ISPOR, CIRS, representing personal, company or Industry views.
Dr. Michael George
Dr George is the Global Therapeutic Area Head for Inflammation, Infectious Diseases and General Medicine at Covance UK. He gained a degree in Neuroanatomy at King’s College London before completing his medical degree at Westminster and Charing Cross Medical School and undertaking postgraduate training in Internal Medicine. He obtained membership of the Royal College of Physicians in the UK and a diploma in pharmaceutical medicine. Dr George started his Pharmaceutical career in Merck working in Medical Affairs in the cardiovascular and metabolic areas before moving to a Global clinical development role at GSK and then latterly Takeda Global Research & Development Europe where he was Development Director and eventually Managing Director of the European development operation. He was responsible for spearheading the set-up of Takeda’s regional development hub in Singapore to cover trials in the rapidly growing Asia Pacific region. With over 21 years of experience in the Pharmaceutical Industry he has held numerous posts of increasing seniority with both Regional and Global responsibility. He has worked across all phases of clinical drug development in multiple therapeutic areas including cardiovascular, metabolic, inflammation & allergy, respiratory and women’s health. His publications include numerous articles in the areas of hypertension, heart failure, diabetic retinopathy and neuro-endocrine modulation.
Dr Varawalla is a Fellow of the College of Physicians & Surgeons of India, was Rhodes Fellow at the University of Oxford where she obtained a doctorate for molecular genetics research and worked a specialist at two of the NHS’s leading hospitals. Dr. Varawalla obtained her MBA from INSEAD following which she joined Accenture’s Healthcare and Life Science business strategy consulting practice in London.
Dr Varawalla is a frequent invited speaker at industry conferences, serves on the editorial board of the Journal for Clinical Studies and is the Program Chair for the DIA.